Results of cost-benefit analysis
| Outcome | Total ($) | Average per patient $ (M±SD) |
| Intervention cost over 4 months | 714 | 5±1 |
| Impact on the cost of drug-related problems | −83 052 | −585±308 |
| Impact on medication costs | ||
| Reduced drug costs | −11 210 | −79±85 |
| Increased drug costs | 7479 | 53±67 |
| Increased lab costs | 4198 | 30±29 |
| Net benefit over the study period (4 months)* | 81 871 | 577 |
| Benefit-to-cost ratio† | 115.7:1 |
The total number of patients is 142.
*The benefits of the intervention include cost avoidance (reduced cost of drug-related problems) + cost savings (reduced drug costs – (increased drug costs + increased lab costs). Net benefit = the benefit ofthe intervention – Intervention cost over 4 months.
† Benefit-to-cost ratio = the benefits of the intervention/intervention cost over 4 months.
M±SD, mean±SD.